Table 4.
Treatment ranking (% probability) and SUCRA values based on failure-free survival results
| AAP | ZA + Doc | Doc | ZA + Cel | ZA | Cel | ADT alone | |
|---|---|---|---|---|---|---|---|
| Best | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Second best | 0.0 | 52.0 | 45.1 | 2.6 | 0.0 | 0.3 | 0.0 |
| Third best | 0.0 | 41.3 | 47.9 | 9.5 | 0.1 | 1.2 | 0.0 |
| Fourth best | 0.0 | 5.7 | 6.7 | 53.3 | 14.7 | 19.1 | 0.5 |
| Fifth best | 0.0 | 1.0 | 0.3 | 21.5 | 42.0 | 31.4 | 3.8 |
| Sixth best | 0.0 | 0.0 | 0.0 | 10.4 | 37.6 | 29.1 | 22.9 |
| Worst | 0.0 | 0.0 | 0.0 | 2.7 | 5.6 | 18.9 | 72.8 |
| SUCRA | 1.0 | 0.7 | 0.7 | 0.4 | 0.3 | 0.3 | 0.1 |
AAP, abiraterone acetate plus prednisolone/prednisone; ADT, androgen-deprivation therapy; Cel, celecoxib; Doc, docetaxel; SUCRA, surface under the cumulative rank; ZA, zoledronic acid.